Press release
Psychosis in Parkinson's and Alzheimer's Disease Market to Reach USD 6.5 Billion by 2034
Psychosis in Parkinson's and Alzheimer's Disease
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71923
Current treatment options are limited, as standard antipsychotics worsen motor and cognitive symptoms. The introduction of novel therapies, such as pimavanserin (Nuplazid) and investigational serotonergic agents, alongside digital health platforms and biomarker-driven psychiatry, is transforming the market outlook.
Market Overview
• Market Size (2024): USD 3.5 billion
• Forecast (2034): USD 6.5 billion
• CAGR (2025-2034): 6.3%
Growth is fueled by rising prevalence of neurodegenerative diseases, FDA/EMA approvals of safer antipsychotics, and integration of digital health monitoring tools.
Key Highlights:
• Pimavanserin remains the only FDA-approved drug specifically for PD psychosis.
• High unmet need in Alzheimer's-related psychosis due to safety issues with traditional drugs.
• AI-driven neuropsychiatric monitoring improving early intervention.
• Pipeline research exploring serotonergic, glutamatergic, and neurosteroid-based agents.
Segmentation Analysis
By Product Type:
• Pharmacological Therapies
o Pimavanserin (Nuplazid - FDA approved for PD psychosis)
o Clozapine, Quetiapine (used cautiously in PD/AD psychosis)
o SSRIs/SNRIs (adjunctive use in behavioral symptoms)
o Pipeline Agents (serotonergic modulators, glutamate-based therapies, neurosteroids)
• Non-Pharmacological Interventions
o Cognitive Behavioral Therapy (CBT) for hallucination coping
o Caregiver Training Programs
• Digital Health Solutions
o AI-Based Behavioral Monitoring
o Telepsychiatry for Elderly Patients
o Virtual Reality (VR) Calming Environments
By Platform:
• Small Molecules (pimavanserin, quetiapine)
• Biologics (emerging neuropsychiatric immunotherapies)
• Digital & Non-Drug Interventions
By Technology:
• AI-Powered Psychiatry Platforms
• Biomarker-Based Diagnostics (CSF, PET imaging for psychosis risk)
• Digital Therapeutics
By End Use:
• Hospitals & Neurology Clinics
• Memory Care Centers
• Home Care Settings
• Research Institutes
By Application:
• Parkinson's Disease Psychosis
• Alzheimer's Disease Psychosis
• Clinical Research
Segmentation Summary:
Pharmacological treatments dominate, but digital health tools, biomarkers, and novel serotonergic/glutamatergic drugs represent the fastest-growing categories.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71923
Regional Analysis
North America
• ~45% share in 2024.
• Strong adoption of pimavanserin and digital monitoring tools.
• FDA supporting neuropsychiatric drug pipelines.
Europe
• ~30% share.
• Germany, UK, and France leading integrated dementia and PD psychosis care.
• EMA pipeline reviews expanding therapy access.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.5%.
• Rising neurodegenerative burden in Japan, China, and India.
• Expanding memory clinics and telepsychiatry adoption.
Middle East & Africa
• Smaller market but rising with aging populations.
• Limited specialized dementia and Parkinson's care centers.
Latin America
• Brazil and Mexico driving demand.
• Growing use of generics and caregiver support platforms.
Regional Summary:
North America and Europe dominate today's market, while Asia-Pacific grows fastest with rising prevalence, healthcare expansion, and digital health adoption.
Market Dynamics
Key Growth Drivers:
• Rising prevalence of PD and AD globally.
• FDA/EMA approvals of safer psychiatric drugs like pimavanserin.
• Growing digital psychiatry platforms for elderly care.
• Increasing focus on caregiver support and burden reduction.
Key Challenges:
• Limited efficacy and high relapse rates with current drugs.
• Safety concerns of antipsychotics in elderly patients.
• High treatment costs and access limitations in low-income countries.
• Underdiagnosis of psychosis in early PD and AD.
Latest Trends:
• Expansion of serotonergic and glutamatergic drug pipelines.
• AI-based digital monitoring for hallucination tracking.
• Integration of telepsychiatry and VR-based therapies.
• Development of biomarker-driven psychiatry for early detection.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71923/psychosis-in-parkinson-s-and-alzheimer-s-disease-market
Competitor Analysis
Major Players in the Market:
• ACADIA Pharmaceuticals Inc. (Pimavanserin - Nuplazid)
• Eli Lilly and Company
• Johnson & Johnson (Janssen Pharmaceuticals)
• Novartis AG
• Pfizer Inc.
• Roche Holding AG (biomarker and neurodegenerative research)
• Biogen Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Lundbeck A/S
• MindMaze (digital neurotherapeutics)
Competitive Summary:
ACADIA dominates with pimavanserin, while Eli Lilly, Roche, and Biogen explore neuropsychiatric drug pipelines. Novartis, Pfizer, and J&J maintain strong CNS portfolios. MindMaze and digital firms pioneer VR and AI psychiatry solutions. Competition is focused on drug innovation, biomarker integration, and digital health expansion.
Conclusion
The Psychosis in Parkinson's and Alzheimer's Disease Market, valued at USD 3.5 billion in 2024, is projected to reach USD 6.5 billion by 2034, growing at a CAGR of 6.3%. Expanding drug pipelines, digital psychiatry, and biomarker-driven approaches will continue to reshape the market.
Key Takeaways:
• Pimavanserin leads PD psychosis treatment, but AD psychosis remains underserved.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• Digital health and AI platforms will improve diagnosis and monitoring.
• Future growth will come from integrated multimodal care models combining pharmacology, digital tools, and caregiver support.
The next decade will move psychosis care in PD and AD from limited symptomatic management toward precision psychiatry and digital integration, creating opportunities for pharma, biotech, and digital innovators.
This report is also available in the following languages : Japanese (パーキンソン病およびアルツハイマー病市場における精神病), Korean (파킨슨병 및 알츠하이머병 시장의 정신병), Chinese (帕金森病和阿尔茨海默病中的精神病市场), French (Marché de la psychose dans la maladie de Parkinson et d'Alzheimer), German (Psychosen im Parkinson- und Alzheimer-Markt), and Italian (Psicosi nel mercato del morbo di Parkinson e di Alzheimer), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71923/psychosis-in-parkinson-s-and-alzheimer-s-disease-market#request-a-sample
Our More Reports:
Voluntary Carbon Credit Market
https://exactitudeconsultancy.com/reports/72383/voluntary-carbon-credit-market
Companion Animal Health Market
https://exactitudeconsultancy.com/reports/72382/companion-animal-health-market
Cannabi Oil Market
https://exactitudeconsultancy.com/reports/72381/oil-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psychosis in Parkinson's and Alzheimer's Disease Market to Reach USD 6.5 Billion by 2034 here
News-ID: 4179624 • Views: …
More Releases from Exactitude Consultancy
Cell Therapy Manufacturing Market to Reach USD 28.4 Billion by 2034, Growing at …
Introduction
Cell therapy has emerged as a transformative pillar of modern medicine, offering the potential to repair, replace, or regenerate damaged tissues and organs. From CAR-T cell therapies for oncology to stem cell therapies for regenerative medicine, the field is redefining treatment paradigms across oncology, neurology, cardiology, and rare diseases.
As clinical pipelines expand and more therapies achieve regulatory approval, demand for efficient and scalable cell therapy manufacturing has surged. Specialized technologies…
Despite safety concerns, adavosertib exhibits early antitumor activity in uterin …
Uterine serous carcinoma (USC) is a rare but highly aggressive subtype of endometrial cancer, accounting for less than 10% of endometrial cancer cases but contributing to a disproportionately high mortality rate. It is often diagnosed at advanced stages, making it difficult to treat with conventional methods.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72873
In recent years, the treatment landscape has expanded beyond chemotherapy and surgery to include targeted therapies,…
Market for Catheter-Related Bloodstream Infections: Overview, Therapies, and Imp …
Catheter-related bloodstream infections (CRBSIs) are among the most common and serious complications associated with intravascular catheters used in hospitals and long-term care settings. These infections can lead to prolonged hospital stays, increased healthcare costs, and higher mortality rates. With the rising use of central venous catheters, particularly among critically ill patients, oncology cases, and those requiring long-term intravenous therapy, the global demand for effective prevention and treatment solutions is growing…
ADC Technology Market to Reach USD 33.7 Billion by 2034, Growing at 13.2% CAGR
Introduction
Antibody-drug conjugates (ADCs) represent one of the most innovative breakthroughs in oncology, combining the target specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. By delivering highly toxic payloads directly to cancer cells, ADCs minimize systemic toxicity and enhance therapeutic efficacy.
As cancer incidence rises worldwide and the limitations of conventional chemotherapy become more evident, ADC technology is gaining momentum. With advancements in linker chemistry, payload design, and next-generation…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
